Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Namodenoson

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Can-Fite Granted Canadian Patent For Namodenoson As Anti-Obesity
    Can-Fite Granted Canadian Patent For Namodenoson As Anti-Obesity

    09 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/09/3234404/0/en/Can-Fite-Receives-Canadian-Patent-Allowance-for-Namodenoson-as-an-Anti-Obesity-Therapy.html

    GLOBENEWSWIRE
    09 Feb 2026
    Share Share
    Can-Fite Wraps Namodenoson Phase 2a Trial in Pancreatic Cancer
    Can-Fite Wraps Namodenoson Phase 2a Trial in Pancreatic Cancer

    20 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/20/3221562/0/en/Can-Fite-Completes-Patient-Enrollment-in-Phase-2a-Pancreatic-Cancer-Study-of-Namodenoson.html

    GLOBENEWSWIRE
    20 Jan 2026
    Share Share
    Can-Fite Provides Update On Clinical And Financial Status
    Can-Fite Provides Update On Clinical And Financial Status

    16 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/16/3206339/0/en/Can-Fite-Provides-Update-on-Clinical-and-Financial-Status.html

    GLOBENEWSWIRE
    16 Dec 2025
    Share Share
    Can-Fite Explores Namodenoson Veterinary Partnerships at BioFIT
    Can-Fite Explores Namodenoson Veterinary Partnerships at BioFIT

    24 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/24/3193378/0/en/Can-Fite-to-Advance-New-Veterinary-Partnership-Opportunities-for-Namodenoson-at-the-BioFIT-2025-Conference.html

    GLOBENEWSWIRE
    24 Nov 2025
    Share Share
    Can-Fite's Namodenoson Yields 9-Yr Cure in Advanced Liver Cancer
    Can-Fite's Namodenoson Yields 9-Yr Cure in Advanced Liver Cancer

    18 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/18/3189858/0/en/Can-Fite-9-Year-Survival-with-Complete-Cure-in-an-Advanced-Liver-Cancer-Patient-Treated-with-Namodenoson.html

    GLOBENEWSWIRE
    18 Nov 2025
    Share Share
    Can-Fite’s Namodenoson Treats Esophageal Varices in Cirrhosis
    Can-Fite’s Namodenoson Treats Esophageal Varices in Cirrhosis

    15 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/15/3149846/0/en/Can-Fite-Reports-Complete-Resolution-of-Esophageal-Varices-in-Decompensated-Cirrhosis-Patient-Treated-with-Namodenoson.html

    GLOBENEWSWIRE
    15 Sep 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.